Refractory trigeminal neuralgia responsive to nabiximols in a patient with multiple sclerosis


      • Nabiximols (Sativex®) is a cannabinoid approved for treatment of multiple sclerosis-related spasticity.
      • It is known that cannabinoids may ameliorate pain, which is a common multiple sclerosis symptom.
      • A patient with a remarkable benefit of nabiximols on trigeminal neuralgia is reported.
      • Nabiximols should be tested for multiple sclerosis symptoms other than spasticity.



      Nabiximols is a cannabinoid compound approved for the treatment of multiple sclerosis (MS)-related spasticity. However, additional symptoms, such as pain, urinary urgency and sleep disturbance, may benefit from treatment.

      Case report

      The present report describes a patient with secondary progressive MS and severe lower limbs spasticity who was started on treatment with nabiximols. The patient also suffered from trigeminal neuralgia, which he was not treating due to inefficacy or side effects of all previously tried medications. After nabiximols initiation the patient experienced a marked benefit on trigeminal neuralgia, which completely resolved, while spasticity responded only partially to treatment.


      Nabiximols mechanism of action is based on the interaction with CB1 and CB2 receptors, which are expressed by central nervous system neurons and are known to modulate pain among other effects. The present case indicates that nabiximols and other cannabinoids need to be further tested for the treatment of trigeminal neuralgia.


      To read this article in full you will need to make a payment


        • Foley P.L.
        • Vesterinen H.M.
        • Laird B.J.
        • Sena E.S.
        • Colvin L.A.
        • Chandran S.
        • MacLeod M.R.
        • Fallon M.T.
        Prevalence and natural history of pain in adults with multiple sclerosis: systematic review and meta-analysis.
        Pain. 2013; 154: 632-642
        • Koppel B.S.
        • Brust J.C.
        • Fife T.
        • Bronstein J.
        • Youssof S.
        • Gronseth G.
        • Gloss D.
        Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the guideline development subcommittee of the American Academy of Neurology.
        Neurology. 2014; 82: 1556-1563
        • Liang Y.C.
        • Huang C.C.
        • Hsu K.S.
        • Takahashi T.
        Cannabinoid-induced presynaptic inhibition at the primary afferent trigeminal synapse of juvenile rat brainstem slices.
        J. Physiol. 2004; 555: 85-96
        • McDonough P.
        • McKenna J.P.
        • McCreary C.
        • Downer E.J.
        Neuropathic orofacial pain: cannabinoids as a therapeutic avenue.
        Int. J. Biochem. Cell Biol. 2014; 55: 72-78
        • Notcutt W.
        • Langford R.
        • Davies P.
        • Ratcliffe S.
        • Potts R.
        A placebo-controlled, parallel- group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex® (nabiximols).
        Mult. Scler. 2012; 18: 219-228
        • Polman C.H.
        • Reingold S.C.
        • Banwell B.
        • et al.
        Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria.
        Ann. Neurol. 2011; 69: 292-302
        • Pozzilli C.
        Advances in the management of multiple sclerosis spasticity: experiences from recent studies and everyday clinical practice.
        Expert Rev. Neurother. 2013; 13: S49-S54
        • Sastre-Garriga J.
        • Vila C.
        • Clissold S.
        • Montalban X.
        THC and CBD oromucosal spray (Sativex®) in the management of spasticity associated with multiple sclerosis.
        Expert Rev. Neurother. 2011; 11: 627-637